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Abstract
Background: In patients presenting with acute liver failure (ALF) prediction of prognosis is vital
to determine the need of transplantation. Based on the evidence that plasma disappearance rate of
indocyanine green (ICG-PDR) correlates with liver cell function, we evaluated the ability of ICG-
PDR measured by pulse dye densitometry to predict outcome in patients with acute liver failure.
Methods: Prospectively markers of hepatocellular injury, synthesis and excretion, including ICG-
PDR were measured daily until liver transplantation, death, discharge from intensive care unit, or
up to 7 days in 25 patients with acute liver failure. Receiver operating curve (ROC) analysis was
performed to assess the value of ICG-PDR to predict outcome in ALF.
Results: The 25 patients analyzed included 18 that recovered spontaneously and 7 that underwent
liver transplantation (n = 6) or died (n = 1). Causes of ALF included viral hepatitis (n = 4), toxic
liver injury (n = 15), ischemic liver injury (n = 2), and cryptogenic liver failure (n = 4). King's college
criteria were fulfilled in 85.7% of patients not recovering spontaneously and in 16.7% of patients
recovering spontaneously. The mean ICG-PDR measured on day 1 in patients recovering
spontaneously was 12.0 ± 7.8%/min and in patients not recovering spontaneously 4.3 ± 2.0%/min
(P = 0.002). By ROC analysis the sensitivity and specificity of an ICG-PDR value ≤ 6.3%/min on study
day 1 were 85.7% and 88.9%, respectively, for predicting a non spontaneous outcome in ALF.
Conclusion: ICG-PDR allows early and sensitive bedside assessment of liver dysfunction in ALF.
Measurement of ICG-PDR might be helpful in predicting the outcome in acute liver failure.
Trial registration: Clinicaltrials.gov, NCT 00245310
Background
Acute liver failure (ALF) is a rare condition in which rapid
deterioration of liver function occurs in previously
healthy individuals. The most prominent causes include
drug-induced liver injury, viral or autoimmune hepatitis,
Wilson disease, ischemia, or unknown reasons [1]. The
most widely accepted definition of ALF includes evidence
of coagulopathy, usually an INR ≥ 1.5, and any degree of
encephalopathy in a patient without pre-existing liver dis-
ease and with an illness of <26 weeks duration [2]. Liver
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transplantation is the treatment of choice, but because
this is only clearly justifiable in patients who would oth-
erwise die, criteria for determining such patients have
been established. Prognostic scoring systems still fail to
achieve success, given the wide variety of aetiologies that
lead to this end stage syndrome. The decision as to
whether a patient will recover with conservative manage-
ment or require transplantation has been the subject of
many different reports and case series; however, the King's
College Criteria remain the current standard for many cli-
nicians [3].
Indocyanine green (ICG) is a water-soluble, inert anionic
compound. After intravenous injection it mainly binds to
albumin and β-lipoproteins in the plasma. ICG is not
metabolized and is almost completely excreted into the
bile without enterohepatic recirculation [4]. Because of
these features, ICG has been studied in assessing liver
function before hepatectomy, in liver transplantation
donors and recipients, in patients with chronic liver fail-
ure, and in critically ill patients as a prognostic factor [5-
11]. Plasma disappearance rate of ICG (ICG-PDR) is the
most commonly used ICG-derived parameter for clinical
and experimental assessment of liver function and should
physiologically be >18%/min [12]. ICG-PDR depends on
ICG uptake by hepatocytes, its excretion into the bile,
blood flow-dependent liver metabolism, and energy sta-
tus. It does not represent the liver blood flow alone. There
are various techniques to assess ICG-PDR in vivo. The
gold standard relies on serial blood sampling after ICG
injection with spectrophotometric analysis of concentra-
tion [9,10]. However, this method is invasive, expensive
and time-consuming. In contrast, a non-invasive pulsed-
ensitometric method uses a transcutaneous system
adapted from pulse oxymetry and a peripheral or central
venous access for ICG injection. This method correlates
well with the invasive method in hemodynamically stable
and mechanically ventilated critically ill patients as well as
hemodynamic unstable patients undergoing liver trans-
plantation [13,14].
Using ICG-PDR we measured residual liver function in
patients with acute liver failure non-invasively. We evalu-
ated the relationship between ICG-PDR and non-sponta-
neous recovery, to serve as a diagnostic marker to identify
candidates who have to be transplanted. We then assessed
the usefulness of this test by examining the correlations
between the results of ICG-PDR and other markers of liver
function.
Methods
Patients
From 01/2006 to 02/2007, 25 consecutive patients who
presented at the University Hospital of Heidelberg with
acute liver failure were prospectively enrolled in this study
after obtaining informed consent. The study protocol was
approved by the ethics committee of the University of
Heidelberg. King's College Hospital criteria and model of
end-stage liver disease score were determined as previ-
ously defined [3,15]. The main demographic and clinical
features of the patients are summarized in Table 1.
The clinical management of the patients and the decision
of whether to transplant a patient were solely left to the
attending physicians discretion blinded to the ICG-PDR
measurements. The decision of the attending staff to list a
patient for transplantation was based on critical evalua-
tion of performance in clinical scores, the patients general
condition and comorbidities as well as careful interpreta-
tion of the clinical course.
Pulse dye densitometry
Pulse dye densitometry was performed using a non-inva-
sive densitometer (LiMON Leberfunktionsmonitor, Pul-
sion Medical Systems AG, Munich, Germany) by one
medical student. The instrument measured arterial ICG
concentration based on the principle of differences in
Table 1: Demographic and clinical features of patients
Variables All (n = 25) Spontanous recovery (n = 18) No spontanous recovery (n = 7) P*
Mean age ± SD 42.1 ± 19.0 38.3 ± 19.4 51.7 ± 15.2 0.090
Sex (% male) 24.0 22.2 28.6 0.744
Mean bilirubin [mg/dL ± SD] 10.2 ± 10.7 6.6 ± 6.5 19.2 ± 14.3 0.079
Mean creatinine [mg/dL ± SD] 1.3 ± 2.2 0.7 ± 0.3 2.7 ± 3.9 0.061
Mean INR ± SD 2.4 ± 1.3 1.9 ± 0.4 3.9 ± 1.6 < 0.001
Mean AST [U/L ± SD] 3244.7 ± 3600.9 2903.0 ± 3625.9 4123.4 ± 3655.9 0.333
Mean ALT [U/L ± SD] 2893.9 ± 2282.9 2772.8 ± 2449.6 3205.3 ± 1920.4 0.397
MELD score ± SD 22.9 ± 8.1 18.8 ± 4.8 33.4 ± 3.7 < 0.001
KCH criteria (% fulfilled) 36.0 16.7 85.7 < 0.001
APACHE II 9.1 ± 6.3 7.0 ± 3.9 14.4 ± 8.3 0.042
*Statistical significance of differences between ALF patients with and without spontanous recovery.
Abbreviations: INR, international normalized ratio; MELD, model for end-stage liver disease; KCH, King's College Hospital; and SD, standard 
deviation.BMC Gastroenterology 2009, 9:91 http://www.biomedcentral.com/1471-230X/9/91
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absorbance between oxyhaemoglobin and ICG (wave-
lengths, 905 nm and 805 nm, respectively). This proce-
dure is similar to the concept of pulse oximetry, in which
arterial oxygen saturation represents the difference in
adsorbance between oxyhaemoglobin and reduced hae-
moglobin (wavelengths 940 nm and 660 nm, respec-
tively). In principle, the ICG-PDR is determined by
monoexponential transformation of the original ICG con-
centration curve, backward extrapolation to the time
point 'zero' (100%), and describing the decay as percent-
age change per time. Taking blood samples is not neces-
sary.
Directly after inclusion in the study a bolus of 25 mg of
ICG (ICG-Pulsion, Pulsion Medical AG, München. Ger-
many) was injected through an intravenous catheter, fol-
lowed immediately by flushing with physiological saline.
Blood ICG concentrations are monitored at every pulse
via an optical probe attached to the patient's finger. ICG-
PDR means the change of ICG concentration over time (in
percent per minute) and reflects the amount of the dye
which is eliminated in percent of the initial value. It is
automatically calculated by drawing the decay curve of
ICG density. After inclusion in the study ICG-PDR was
determined daily until death, liver transplantation, or dis-
charge from intensive care unit for up to 7 days. During
the study no adverse events attributable to ICG applica-
tion were noted. Blood samples were taken daily during
the study to assess serum concentrations of the following
liver function tests and markers for disease severity/liver
injury: aspartate aminotransferase (AST), alanine ami-
notransferase (ALT), bilirubin, creatinine, cholinesterase,
albumin, INR.
Statistical analysis
The Mann-Whitney U test was used to examine differences
in laboratory test results, ICG-PDR values, Apache II
scores, and MELD scores between 2 groups and the
Kruskal Wallis test to examine differences between more
than 2 groups. For the measures of diagnostic accuracy
95% confidence intervals are reported. Correlations
between ICG and results of other laboratory tests and
scores were determined using Pearson's correlation coeffi-
cient. P values less than 0.05 were considered statistically
significant.
Results
Characteristics of the study population and outcome
The study group included 19 women and 6 men with a
mean age of 42.1 years (range: 18 - 80 years). Causes of
ALF included viral hepatitis (n = 4), toxic liver injury (n =
15), ischemic liver injury (n = 2), and cryptogenic liver
failure (n = 4). ALF patients with toxic liver injury
included four patients with acetaminophen (AAP) and 11
patients with other drug or Amanita mushroom poison-
ing (non-acetaminophen, NAAP). The total of 25 patients
included 18 that recovered spontaneously and 7 that
underwent liver transplantation (n = 6) or died (n = 1).
Among the different causes, patient numbers with versus
without spontaneous recovery were: viral hepatitis (2/2),
AAP (4/0), NAAP (8/3), ischemic (1/1), and cryptogenic
liver failure (3/1).
The laboratory data on admission showed that the
patients that recovered spontaneously had a significantly
lower INR (1.9 ± 0.4 vs. 3.9 ± 1.6, P < 0.001). Bilirubin
and creatinine in serum were both higher in patients that
did not recover spontaneously, although the difference
was not significant (Table 1). The MELD score on admis-
sion was significantly higher in the patients that did not
recover spontaneously (33.4 ± 3.7 vs. 18.8 ± 4.8, P <
0.001).
King's college criteria were fulfilled in 6 of 7 patients not
recovering spontaneously and negative in 15 of 18
patients recovering spontaneously, resulting in a sensitiv-
ity of 85.7% and a specificity of 83.3%.
Measurement of ICG-PDR in ALF patients
ICG-PDR was measured daily in each patient from admis-
sion for seven consecutive days. Measurements were ter-
minated earlier in patients that were liver transplanted,
died, or were discharged from intensive care unit. In all of
the patients, the first ICG-PDR measurement was made
within 24 h after admission to the intensive care unit. The
course of ICG-PDR values for each ALF patient is dis-
played in Figure 1A for patients recovering spontaneously
and in Figure 1B for patients that did not recover sponta-
neously.
The ICG-PDR measured at day 1 was significantly lower in
patients not recovering spontaneously than in spontane-
ously recovering patients (mean, 4.3 ± 2.0%/min; median
13.0; vs. mean, 12.0 ± 7.8%/min; median 4.2, respectively
(P = 0.002)) (Figure 2A). The lowest ICG-PDR measured
in each individual during the study was also significantly
lower in patients not recovering spontaneously than in
spontaneously recovering patients (mean, 3.4 ± 1.5%/
min; median 6.9; vs. mean, 9.4 ± 7.3%/min, median, 3.2,
respectively (P = 0.018)) (Figure 2B). There was no statis-
tically significant difference between the ICG-PDR meas-
ured at day 1 and the lowest ICG-PDR measured in each
individual patient. When comparing patients' ICG-PDR
with respect to the aetiology of ALF no statistically signif-
icant differences between the 5 groups could be detected.
This was true for ICG-PDR at day 1 and for the lowest ICG-
PDR measured in each individual (Figures 2C and 2D).
ROC statistics using ICG-PDR measured day 1 (Figure 3A)
revealed an AUC of 0.90 (95% confidence interval, 0.77-BMC Gastroenterology 2009, 9:91 http://www.biomedcentral.com/1471-230X/9/91
Page 4 of 7
(page number not for citation purposes)
1.03) and ROC statistics using lowest ICG-PDR measured
in each individual ALF patient (Figure 3B) revealed an
AUC of 0.81 (95% confidence interval, 0.64-0.98). An
ICG-PDR ≤ 6.3%/min measured on day 1 predicted death
or transplantation with a sensitivity of 85.7% (95% confi-
dence interval, 42.0%-99.3%) and a specificity of 88.9%
(95% confidence interval, 64.0%-98.0%). The lowest
ICG-PDR measured in each individual patient at any
timepoint = 5.3%/min predicted death or transplantation
with a sensitivity of 85.7% (95% confidence interval,
42.0%-99.3%) and a specificity of 66.7% (95% confi-
dence interval, 41.1%-85.6%).
When analyzing correlation of ICG-PDR measured at day
1 with INR, bilirubin, creatinine, AST, ALT, Apache II
score, and MELD score, significant correlations were
obtained for INR (r = -0.41; P = 0.043), bilirubin (r = -
0.53, P = 0.006), and MELD score (r = -0.67; P < 0.001).
Time course of indocyanine green plasma disappearance rate (ICG-PDR) in ALF patients with (A) spontaneous recovery (n =  18) and (B) no spontaneous recovery (n = 7) Figure 1
Time course of indocyanine green plasma disappearance rate (ICG-PDR) in ALF patients with (A) spontane-
ous recovery (n = 18) and (B) no spontaneous recovery (n = 7). ICG-PDR was obtained daily during the study (day 1 to 
7 or until liver transplantation, death, or discharge from intensive care unit).
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Discussion
Based upon the available data, the current prognostic
scoring systems have not consistently demonstrated relia-
ble accuracy in predicting outcome from ALF and the sub-
sequent need for liver transplantation [16]. In this study
we prospectively evaluated ICG-PDR in predicting out-
come in 25 patients with ALF.
ICG-PDR measured at day 1 (after inclusion in the study)
below 6.3%/min had a sensitivity of 85.7% and a specifi-
city of 88.9% in predicting outcome in ALF patients.
When analyzing the lowest ICG-PDR values obtained in
each individual patient during the study period (day 1 to
7 or until liver transplantation, death, or discharge from
intensive care unit, respectively) the sensitivity remained
high, but specificity was slightly lower. Our results coin-
cide with a previously published retrospective analysis of
Figure 2 
Indocyanine green plasma disappearance rate (ICG-PDR) in patients with acute liver failure. Distribution of data
presented as a box and whisker plots: 25th percentile, median, 75th percentile, maximum, and outliers (circles). The bold
asterisk indicates statistical significance (Mann-Whitney U test). (A) ICG-PDR measured on day 1 in patients with ALF that
recovered spontaneously (SR) or did not recover spontaneously (NSR). ICG-PDR is significantly lower in patients that did not
recover spontaneously than in patients that recovered spontaneously (P = 0.002). (B) Lowest ICG-PDR measured throughout
the study (day 1-7) in patients with ALF that recovered spontaneously (SR) or did not recover spontaneously (NSR). ICG-PDR
is significantly lower in patients that did not recover spontaneously than in patients that recovered spontaneously (P = 0.018).
(C) ICG-PDR measured on day 1 in different causes of ALF including viral hepatitis, acetaminophen (AAP), and non-acetami-
nophen (NAAP) induced liver injury, ischemic liver injury, and unknown causes. The number of patients in each category is
indicated. Using Kruskal-Wallis test, no statistical difference was observed between the different etiological ALF groups. (D)
Lowest ICG-PDR measured throughout the study (day 1-7) in different causes of ALF including viral hepatitis, acetaminophen
(AAP), and non-acetaminophen (NAAP) induced liver injury, ischemic liver injury, and unknown causes. The number of patients
in each category is indicated. Using Kruskal-Wallis test, no statistical difference was observed between the different etiological
ALF groups.
A                                                                B
C                                                                D
* *
SR                              NSR    SR                              NSR   
Viral AAP     NAAP  Ischemic Unknown
(n=4)     (n=4)     (n=11)     (n=2)        (n=4)
Viral AAP     NAAP  Ischemic Unknown
(n=4)     (n=4)     (n=11)     (n=2)        (n=4)BMC Gastroenterology 2009, 9:91 http://www.biomedcentral.com/1471-230X/9/91
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ICG-PDR in seven patients presenting with acute liver fail-
ure [17]. In this report ICG-PDR values greater than 5%/
min were a prognostic factor for hepatic recovery. How-
ever, although in our cohort the predictive value of ICG-
PDR is promising, caution has to be taken with the inter-
pretation of single ICG-PDR measurement as ICG-PDR
may vary from day to day (Figure 1). One could speculate
that the observed variation of ICG-PDR values may in part
be caused by an - to date speculative - additional extrahe-
patic ICG elimination or decay. This hypothesis is sup-
ported by the previously published observation of ICG
clearance even in anhepatic patients [18]. Nevertheless,
our results suggest that ICG-PDR measured early during
the course of ALF is a valuable prognostic marker for pre-
dicting outcome of ALF. One advantage is its prognostic
value early in the course of ALF. Thus, measurement of
ICG-PDR might help to timely identify those patients
with ALF who are likely to benefit from liver transplanta-
tion.
To date the most widely used criteria are the King's college
criteria [3]. In a recent meta-analysis, Bailey et al. [16]
compared different prognostic criteria used to determine
the need for liver transplantation and found that all prog-
nostic models presently available lack sensitivity and may
miss patients requiring transplantation. In this meta-anal-
ysis King's college criteria performed best, with a sensitiv-
ity of 69% and a specificity of 92%. In our study sensitivity
and specificity of King's college criteria in predicting out-
come in ALF patients were 85.7% and 83.3%, and thus in
the range of the results of the studies included in the meta-
analysis of Bailey et al. [16]. Compared to the results
obtained in the meta-analysis of Bailey et al. [16] the prog-
nostic value of ICG-PDR in our recent study is superior to
King's college criteria with respect to its sensitivity and
equal with respect to its specificity. However, the evalua-
tion of the performance of King's College criteria in our
and other studies must be interpreted with care as fulfil-
ment of the criteria has most likely influenced the clinical
decision whether to transplant a patient or not. In addi-
tion the number of patients analyzed in our present study
is limited. Thus, future studies in larger cohorts will have
to follow.
Clinical studies in ALF patients are often limited because
of heterogeneous aetiologies, the small number of cases,
and difficulties in predicting the patient's outcome with-
out transplantation. In our present study predicting the
spontaneous outcome of six of the seven patients not
recovering spontaneously and receiving liver transplanta-
tion can only be assumed fatal. However, as the fatal out-
come in these is only an assumption and part may have
survived without liver transplantation the calculated ICG-
PDR test performances may be inferior to that stated.
In general, ICG removal from blood depends on liver
blood flow, parenchymal cellular function and biliary
excretion [19,20]. ICG-PDR is a complex measure of both,
sinusoidal perfusion as well as hepatic cell membrane
function, and thus, reflects a functional reserve of intact
hepatocytes which participate in maintained nutritional
perfusion [21]. In our study, ICG-PDR allowed early and
sensitive detection of spontaneous recovery from ALF,
which might be helpful in clinical management. A non-
Predictive discrimination of (A) ICG-PDR measured at day 1  of study and (B) the lowest ICG-PDR measured in each ALF  patient during the study as determined by receiver operating  characteristics (ROC) plot analysis Figure 3
Predictive discrimination of (A) ICG-PDR measured 
at day 1 of study and (B) the lowest ICG-PDR meas-
ured in each ALF patient during the study as deter-
mined by receiver operating characteristics (ROC) 
plot analysis. The ROC analysis indicates the ICG-PDR 
threshold for the best compromise sensitivity/specificity to 
predict ALF outcome (AUC, area under the curve; CI, confi-
dence interval).
A
B
ICG-PDR
Cutoff: 6.3%/min
Sensitivity: 85.7%
Specificity: 88.9%
AUC: 0.90, CI: 95% 
ICG-PDR
Cutoff: 5.3%/min
Sensitivity: 85.7%
Specificity: 66.7%
AUC: 0.81, CI: 95% BMC Gastroenterology 2009, 9:91 http://www.biomedcentral.com/1471-230X/9/91
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spontaneous recovery from ALF was associated with high
ICG retention rates. The advantage of the method used in
our study is that ICG-PDR can be measured noninvasively
at the bedside by a transcutaneous system even in criti-
cally ill patients and results can be obtained within 6-8
minutes [13]. Normal values for ICG-PDR are considered
to be over 18%/min. In our study only one patient pre-
senting with ALF had an ICG-PDR in the normal range.
ICG is known to be a safe substance, as side effects are very
rare (1:40000). Since ICG contains iodine, however, it
should not be used in patients with iodine allergy or thy-
reotoxicosis.
Conclusion
ICG-PDG is a valuable dynamic liver function tool to pre-
dict outcome in patients suffering from ALF early during
its course. Because of the possibility of its user-friendly
non-invasive bedside assessment, we suggest to use ICG-
PDR together with other clinical variables to monitor
progress or reversal of liver failure.
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